Achieve Clinical Data Transparency with the 4 Cs of Collaboration Blog Post
In this blog, we look at how you can enhance clinical data transparency and make data informed decisions with the 4 Cs of collaboration.
Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region Blog Post
Abstract The integration of MID3 offers a transformative opportunity for the MENA region to advance pharmaceutical research and healthcare through sophisticated quantitative models like population PK/PD and PBPK modeling. 教育...
Simcyp™ In Vitro Data Analysis (SIVA) Toolkit Blog Post
Download PDF
Unlock Global Regulatory Success: Overcoming Early Drug Development Challenges [APAC Webinar] Blog Post
Summary Navigating early drug development is critical to ensuring the long-term success of therapeutic candidates. このウェビナーでは、一般的に直面する課題を克服するための主要戦略について、アジアとアメリカの専門家の見識を交えて解説していきます。...
Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters Blog Post
Rajesh Krishna, PhD 2025年1月10日 Friedreich’s Ataxia (FA) is a rare, genetic, and progressive neurodegenerative disorder. A defect in the Frataxin (FXN) gene causes FA. FXN is essential for...
Certara Appoints New Head of Biometrics, Data Science, and Access Blog Post
2025年1月10日 RADNOR, PA. – 2025年1月10日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) はCERT), a global leader in model-informed drug development, today announced the appointment of Tiffany Woodworth as Head of Biometrics, Data...
Solving Drug Development Challenges with Model-Based Meta-Analysis (MBMA) Blog Post
Summary In this on-demand webinar, "MBMA: Optimizing Drug Development with Aggregate Clinical Trial Data and Predictive Models," Matt Zierhut shares insights on using clinical trial and real-world data. You'll learn...
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease Blog Post
論文: The Journal of Prevention of Alzheimer’s Disease The Phase 1 INTERCEPT-AD study evaluated sabirnetug (ACU193), a monoclonal antibody targeting amyloid-beta oligomers (AβOs), in participants with early symptomatic Alzheimer’s disease...T6 Service Category Page
Product nameLorem ipsum dolor sit amet consectetur urna vulputate metus nisi tempor heading This is custom heading element Lorem ipsum dolor sit amet consectetur. Donec diam risus volutpat tempor. Massa... 
